About the Landscape Review
Stay ahead of the curve by downloading the Beacon Immune Tolerance H1 2023 Landscape Review to understand the latest developments in the field, focusing on the top disease indications. Don’t miss out on valuable insights for your drug development strategies.
The review includes:
- The current drug landscape with a particular emphasis on top disease indications, highlighting the versatile applications of Immune Tolerance assets.
- An overview of the trial landscape including the phase distribution of clinical trials investigating different modalities, including autoimmune, alloimmune, autoinflammatory, and allergy-related disease indications.
- A review of the 2023 regulatory announcements. Staying informed about regulatory announcements that could impact your operations and the industry is essential.
Please note that some information has been removed from the downloadable content below. If you would like to receive the complete version and speak with one of our immune tolerance specialists, please do not hesitate to contact email@example.com to discuss your drug development data needs.
Beacon Immune Tolerance
How the most complete immune tolerance database can help you
What we cover
Beacon Immune Tolerance covers all pharmaceutical interventions used to treat autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies.
The solution encapsulates all drugs and therapies within the immune-mediated disease space from small molecules to CAR T therapy.
How Beacon Immune Tolerance works
All Immune Tolerance pages will have unique data fields that will help speed up the research process. These data fields include:
- Autoantigen specificity
- Mechanism of Action
- Cell Source
- Cell Type
- Delivery System
- Editing Technology
- Target Organ/Cell
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the immune tolerance space.